- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07616518
Dynamic Trajectories of Pupillary Light Reflex Parameters and Prognosis in Critically Ill Patients: A Multicenter Prospective Cohort Study (PUPIL)
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Critically ill patients admitted to emergency intensive care units often have complex underlying conditions, rapid changes in disease severity, fluctuating organ function, and multiple therapeutic influences. Conventional assessment tools, including vital signs, Glasgow Coma Scale, RASS, CPOT, APACHE II, laboratory tests, and imaging examinations, are important in clinical practice but may be limited by subjectivity, intermittent availability, or reduced reliability in patients receiving sedation, analgesia, mechanical ventilation, or organ support.
The pupillary light reflex is a classic component of neurological examination. Automated quantitative pupillometry provides objective and reproducible measurements of pupillary light reflex parameters, including pupil diameter, constriction velocity, dilation velocity, constriction percentage, maximum constriction velocity, and latency. These parameters may reflect brainstem reflex function, autonomic nervous system activity, medication effects, pain, circulatory status, and systemic stress responses in critically ill patients.
This study will enroll adult critically ill patients admitted to participating emergency intensive care units. After written informed consent is obtained from the participant or a legally authorized representative, baseline demographic data, primary diagnosis, disease severity scores, treatment information, organ support, sedation and analgesia status, vasoactive medication use, and vital signs will be collected. Pupillary light reflex parameters will be measured using a handheld automated quantitative pupillometer once daily during the first 7 days after EICU admission, or until EICU discharge or death, whichever occurs first. Additional measurements may be performed when clinically indicated.
The primary analysis will focus on the dynamic trajectory of constriction velocity during the early EICU period. Dilation velocity, pupil diameter, constriction percentage, maximum constriction velocity, and latency will be analyzed as supplementary pupillary light reflex parameters. Group-based trajectory modeling will be used to identify distinct longitudinal trajectory patterns of pupillary light reflex parameters.
The primary outcome is 90-day functional outcome assessed by the Glasgow Outcome Scale-Extended. Unfavorable functional outcome is defined as a GOS-E score of 4 or lower, and death during follow-up will be included in the GOS-E scoring system. The secondary outcome is discharge outcome, which will be analyzed primarily as a binary outcome. Favorable discharge outcome is defined as discharge home or transfer to a rehabilitation facility. Unfavorable discharge outcome is defined as in-hospital death, discharge to hospice or long-term care facility, or discharge against medical advice. Transfer to a higher-level hospital or another medical institution for continued treatment will be recorded as an indeterminate disposition and further followed when feasible.
This study will further evaluate whether dynamic trajectories of pupillary light reflex parameters provide additional prognostic value beyond conventional static measurements and clinical variables. No treatment assignment or intervention will be performed as part of this study. All clinical management decisions will be made by the treating physicians according to routine clinical practice.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Danni Jin, MD
- Numero di telefono: +8615825512455
- Email: 670251925@qq.com
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Age 18 years or older.
- Admission to the emergency intensive care unit.
- Critically ill patients with an expected EICU stay longer than 48 hours.
- Written informed consent obtained from the participant or legally authorized representative.
Exclusion Criteria:
- Severe ocular disease, severe ocular trauma, postoperative ocular status, or other conditions that prevent reliable pupillary measurement.
- Known neuro-ophthalmic disorders that may affect the pupillary light reflex, such as oculomotor nerve palsy.
- Use of topical ophthalmic medications during the study period that may significantly affect pupillary response, when their effects cannot be accurately recorded or evaluated.
- Pregnancy or breastfeeding.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
|---|
|
Adult critically ill patients admitted to the EICU
Adult critically ill patients admitted to emergency intensive care units who meet the eligibility criteria will be enrolled in a single prospective observational cohort.
Participants will undergo quantitative pupillometry during the first 7 days after EICU admission, or until EICU discharge or death, whichever occurs first.
Clinical information, treatment data, discharge outcome, and 90-day functional outcome will be collected.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
90-Day Functional Outcome Assessed by the Glasgow Outcome Scale-Extended
Lasso di tempo: 90 days after disease onset
|
Functional outcome will be assessed using the Glasgow Outcome Scale-Extended at 90 days after disease onset.
Unfavorable functional outcome is defined as a GOS-E score of 4 or lower.
Participants who die during follow-up will be included in the GOS-E scoring system, and the 90-day mortality rate will be reported separately.
|
90 days after disease onset
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Discharge Outcome
Lasso di tempo: From EICU admission to hospital discharge; indeterminate transfers will be followed up to 90 days when feasible
|
Discharge outcome will be analyzed primarily as a binary outcome: favorable versus unfavorable discharge outcome.
Favorable discharge outcome is defined as discharge home or transfer to a rehabilitation facility.
Unfavorable discharge outcome is defined as in-hospital death, discharge to hospice, transfer to a long-term care facility, or discharge against medical advice.
Transfer to a higher-level hospital or another medical institution for continued treatment will be recorded as an indeterminate disposition and further followed when feasible.
|
From EICU admission to hospital discharge; indeterminate transfers will be followed up to 90 days when feasible
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Mao Zhang, MD, Second Affiliated Hospital, School of Medicine, Zhejiang University
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 20260245
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .